DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
IPO Year: 1987
Exchange: NASDAQ
Website: dentsplysirona.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/7/2024 | Outperform → Market Perform | Leerink Partners | |
| 10/25/2024 | $34.00 → $29.00 | Buy | Needham |
| 8/20/2024 | $34.00 | Buy | Needham |
| 2/26/2024 | $42.00 | Outperform | Leerink Partners |
| 11/16/2023 | $35.00 | Buy | Needham |
| 11/10/2023 | Mkt Perform → Outperform | William Blair | |
| 1/12/2023 | Underperform → Mkt Perform | William Blair | |
| 8/5/2022 | Mkt Perform → Underperform | William Blair | |
| 6/2/2022 | $58.00 → $47.00 | Neutral → Buy | UBS |
| 4/20/2022 | $46.00 | Overweight → Neutral | Piper Sandler |
Net sales of $951 million increased 0.5%, organic sales increased 1.3%GAAP gross margin of 52.1%, GAAP net loss of ($494) million or loss per share of ($2.46)Adjusted EBITDA margin of 17.9%, adjusted EPS of $0.50Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the third quarter of 2024. Third quarter net sales of $951 million increased 0.5% (organic sales increased 1.3%) compared to the third quarter
CHARLOTTE, N.C., Oct. 25, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it will host a conference call to discuss its Byte Aligner business. Dentsply Sirona's management team will host an investor conference call and live webcast on October 25, 2024, at 9:00 am ET. For those planning to participate on the call, please register at https://register.vevent.com/register/BI91fb506c8c2944bca6e65629062dd357. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional
Voluntarily Suspends Sales and Marketing of Byte Aligners and Impression Kits Provides Select Preliminary Third Quarter 2024 Results CHARLOTTE, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), today announced the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products. The Company's decision was made in consultation with the U.S. Food and Drug Administration (FDA). In connection with this review, and Dentsply Sirona's proactive efforts to continuously improve its processes, the Comp
Since the launch of its sustainability strategy "BEYOND: Taking Action for a Brighter World" in 2021, Dentsply Sirona has worked diligently to advance sustainability within the company as well as throughout the industry. Dentsply Sirona's latest sustainability report is renewed evidence of the great dedication the company and its employees bring to the table every day. CHARLOTTE, N.C., Oct. 15, 2024 /PRNewswire/ -- Dentsply Sirona, the world's largest manufacturer of professional dental products and technologies and a leading provider of continence care solutions, published its 2023 Sustainability Report over the past weekend during DS World Las Vegas. This annual clinical education event fo
CHARLOTTE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, November 7, 2024, at 8:30 am ET to review its third quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register.
Dentsply Sirona's next-generation intraoral scanner opens a new era of digital patient care, allowing scanning directly to the cloud on any internet-connected device. Cloud-native, wireless, and highly versatile — this is Primescan 2. Building upon the proven1 scanning technology of Primescan and with the ability to scan directly to the cloud on any internet-connected device, Primescan 2 can help practices expand their treatment offerings, save time in daily workflows, and deliver enhanced care and comfort to their patients. CHARLOTTE, N.C., Sept. 5, 2024 /PRNewswire/ -- Dentsply Sirona (NASDAQ:XRAY) continues to pave the way for the future of digital dentistry with the introduction of a new
CHARLOTTE, N.C., Aug. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its participation at upcoming conferences. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 9:15 am ETBaird Global Healthcare Conference on September 10, 2024, at 9:40 am ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a
CHARLOTTE, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Executive Vice President and Chief Financial Officer Glenn Coleman will resign effective November 7, 2024, to assume an executive position at another public company. The Company has initiated a search process to identify its next CFO with the assistance of a leading executive search firm. "On behalf of the entire Dentsply Sirona team, I want to extend our deepest gratitude to Glenn for his leadership and many contributions to our Company over the last two years," said Simon Campion, President and Chief Executive Officer. "During his tenure, Glenn
Net sales of $984 million decreased (4.2%), organic sales decreased (2.3%)GAAP gross margin of 51.9%, GAAP net loss of ($4) million or loss per share of ($0.02)Adjusted EBITDA margin of 17.5%, adjusted EPS of $0.49Revised FY24 outlook: organic sales down (1%) to flat (previously flat to up 1.5%); adjusted EPS of $1.96 to $2.02 (previously $2.00 to $2.10)Company repurchased $150 million of its common stock in Q2 2024; expects to repurchase $100 million of its common stock in Q3 2024Second phase of transformation includes an expected reduction in annualized operating expenses of $80 to $100 million over approximately 12 to 18 months CHARLOTTE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- D
CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Wednesday, July 31, 2024, at 8:30 am ET to review its second quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://re
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Baird analyst Jeffrey Johnson maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $33 to $31.
In the preceding three months, 10 analysts have released ratings for Dentsply Sirona (NASDAQ:XRAY), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 3 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $32.5, a high estimate of $38.00, and a low estimate of $27.00. Observing
Stifel analyst Jonathan Block maintains Dentsply Sirona (NASDAQ:XRAY) with a Hold and lowers the price target from $30 to $28.
Evercore ISI Group analyst Elizabeth Anderson maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and lowers the price target from $28 to $27.
Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and maintains $38 price target.
During the last three months, 8 analysts shared their evaluations of Dentsply Sirona (NASDAQ:XRAY), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 3 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 3 0 0 3M Ago 0 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $34.12, with a high estimate of $41.00 and a low estimate of $28.00. A negative shift in sentiment is evident as
Evercore ISI Group analyst Elizabeth Anderson maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and lowers the price target from $35 to $28.
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. DENTSPLY SIRONA The Trade: DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory T Lucier acquired a total of 3,577 shares at a
Throughout the last three months, 10 analysts have evaluated Dentsply Sirona (NASDAQ:XRAY), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 3 0 0 Last 30D 0 0 1 0 0 1M Ago 1 3 2 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.0, a high estimate of $42.00, and a low estimate of $30.00. Observing a downward trend, the current average is 3.37% lower t
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)
SD - DENTSPLY SIRONA Inc. (0000818479) (Filer)
S-8 - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)
Leerink Partners downgraded Dentsply Sirona from Outperform to Market Perform
Needham reiterated coverage of Dentsply Sirona with a rating of Buy and set a new price target of $29.00 from $34.00 previously
Needham reiterated coverage of Dentsply Sirona with a rating of Buy and set a new price target of $34.00
Leerink Partners initiated coverage of Dentsply Sirona with a rating of Outperform and set a new price target of $42.00
Needham initiated coverage of Dentsply Sirona with a rating of Buy and set a new price target of $35.00
William Blair upgraded Dentsply Sirona from Mkt Perform to Outperform
William Blair upgraded Dentsply Sirona from Underperform to Mkt Perform
William Blair downgraded Dentsply Sirona from Mkt Perform to Underperform
UBS upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $47.00 from $58.00 previously
Piper Sandler downgraded Dentsply Sirona from Overweight to Neutral and set a new price target of $46.00
Credo Technology Group Holding Ltd ("Credo" or the "Company") (NASDAQ:CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved power efficiency as data rates and corresponding bandwidth requirements increase throughout the data infrastructure market, today announced the appointment of Clyde Hosein to the Company's board of directors effective April 3, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401894812/en/Credo Technology Group Holding Ltd Announces Appointment of Industry Veteran Clyde Hosein to Board of Directors (Photo: Business Wire) "Clyde's appointment to the Credo boar
NEW YORK, March 27, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Solventum Corp. (NYSE:SOLV) will be added to the S&P 500 effective prior to the open of trading on Monday, April 1, replacing V.F. Corp. (NYSE:VFC), which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Wednesday, April 3. V.F. will replace ModivCare Inc. (NASD: MODV) in the S&P SmallCap 600 also effective prior to the open of trading on April 3. S&P 500 and 100 constituent 3M Co. (NYSE:MMM) is spinning off Solventum in a transaction expected to be completed April 1. Following the spin-off, the parent 3M will rema
CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Eric K. Brandt, who has served as a Director on the Company's Board of Directors (the "Board") for nearly twenty years and as Chairman of the Board for six years, has informed the Board of his intention to retire at the May 2024 annual meeting and that he will not be standing for re-election. Mr. Brandt commented, "As I think back on the past two decades and all of the challenges we've navigated together, I am grateful for the talented and dedicated individuals with whom I have had the privilege to serve. I am proud of the strong and diverse Boar
CHARLOTTE, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Mr. Brian Gladden has been appointed to its Board of Directors (the "Board"), effective January 1, 2024, to fill the vacancy from Mr. Harry M. Jansen Kraemer, Jr.'s retirement on December 31, 2023. "On behalf of Dentsply Sirona and the Board of Directors, I am pleased to welcome Brian Gladden to the Board," said Eric K. Brandt, Non-Executive Chairman of the Board. "Brian brings more than 35 years of experience with a proven track record in setting strategic vision, building world-class organizations, and driving business growth and transformation.
First-of-its-kind Solution Addresses Sweeping Shifts in Dental Labor Market, Empowering Professionals and Practices Across the US; Appoints Industry Veteran as Chief Commercial Officer PHOENIX, Aug. 16, 2023 /PRNewswire/ -- Toothio, the on-demand dental staffing platform connecting qualified professionals with practices, today announced a $4 million seed round led by Craft Ventures with participation from Burst Capital, Moving Capital, Revere Partners, and Rho Capital Partners. This investment follows an initial backing from AZ Crown, founders of Insight Enterprises (NASDAQ:NSIT). The capital infusion will be used to accelerate Toothio's growth by enhancing its technology, expanding into key
CHARLOTTE, N.C., Sept. 22, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Glenn Coleman has been appointed Executive Vice President and Chief Financial Officer, effective September 26, 2022. He succeeds Barbara Bodem, who has served as Interim Chief Financial Officer since May 2022. Ms. Bodem will remain with the company and continue to serve as an advisor to Mr. Coleman until October 24, 2022. Mr. Coleman brings 30 years of financial management expertise to Dentsply Sirona. He joins the Company from Integra Lifesciences Holdings Corporation ("Integra"), where he most recently served as Executive Vice President and Chi
CHARLOTTE, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Dentsply Sirona Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Simon Campion has been appointed President and Chief Executive Officer and will join the Company's Board of Directors ("Board"), effective September 12, 2022. He succeeds John Groetelaars, who has served as Interim Chief Executive Officer since April 2022. Mr. Groetelaars will continue to serve on the Board. Mr. Campion joins Dentsply Sirona from Becton, Dickinson and Company ("BD"), where he most recently served as Executive Vice President and President of the Medical segment and prior to that served as President of the Interventional segment fol
John Groetelaars Named Interim Chief Executive Officer Barbara Bodem Named Interim Chief Financial Officer Company Provides Update on Anticipated First Quarter Financial Results CHARLOTTE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced the appointment of John Groetelaars, who serves on Dentsply Sirona's Board of Directors, as Interim Chief Executive Officer. He succeeds Don Casey, who has been terminated as CEO and will cease to serve as a member of the Company's Board, effective immediately. The Board has initiated a search to identify the Company's next CEO and has retained a leading executive search fir
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit
CHARLOTTE, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona") (NASDAQ:XRAY) today announced that Mr. John P. Groetelaars has been appointed to its Board of Directors (the "Board"), increasing the size of its Board from eleven to twelve members. "We are pleased to welcome John Groetelaars to the Dentsply Sirona Board of Directors," said Eric K. Brandt, Non-Executive Chairman of the Board. "John brings more than 30 years of MedTech experience with 20 years of international experience, including as the former CEO of Hillrom. John's deep medical technology experience and leadership roles will be a valuable addition to our Board of Directors. We look forward t
Net sales of $951 million increased 0.5%, organic sales increased 1.3%GAAP gross margin of 52.1%, GAAP net loss of ($494) million or loss per share of ($2.46)Adjusted EBITDA margin of 17.9%, adjusted EPS of $0.50Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the third quarter of 2024. Third quarter net sales of $951 million increased 0.5% (organic sales increased 1.3%) compared to the third quarter
CHARLOTTE, N.C., Oct. 25, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it will host a conference call to discuss its Byte Aligner business. Dentsply Sirona's management team will host an investor conference call and live webcast on October 25, 2024, at 9:00 am ET. For those planning to participate on the call, please register at https://register.vevent.com/register/BI91fb506c8c2944bca6e65629062dd357. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional
Voluntarily Suspends Sales and Marketing of Byte Aligners and Impression Kits Provides Select Preliminary Third Quarter 2024 Results CHARLOTTE, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), today announced the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products. The Company's decision was made in consultation with the U.S. Food and Drug Administration (FDA). In connection with this review, and Dentsply Sirona's proactive efforts to continuously improve its processes, the Comp
CHARLOTTE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, November 7, 2024, at 8:30 am ET to review its third quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register.
Net sales of $984 million decreased (4.2%), organic sales decreased (2.3%)GAAP gross margin of 51.9%, GAAP net loss of ($4) million or loss per share of ($0.02)Adjusted EBITDA margin of 17.5%, adjusted EPS of $0.49Revised FY24 outlook: organic sales down (1%) to flat (previously flat to up 1.5%); adjusted EPS of $1.96 to $2.02 (previously $2.00 to $2.10)Company repurchased $150 million of its common stock in Q2 2024; expects to repurchase $100 million of its common stock in Q3 2024Second phase of transformation includes an expected reduction in annualized operating expenses of $80 to $100 million over approximately 12 to 18 months CHARLOTTE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- D
CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Wednesday, July 31, 2024, at 8:30 am ET to review its second quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://re
CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 12, 2024, to holders of record as of June 28, 2024. About Dentsply Sirona Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solution offering including dental and oral health
Net sales of $953 million decreased (2.6%), organic sales decreased (1.9%)GAAP gross margin of 53.1%, GAAP net income of $18 million or $0.09 per shareAdjusted EBITDA margin of 16.8%, adjusted EPS of $0.42Maintaining FY24 outlook for organic sales and adjusted EPS, trending towards the low-end of both ranges; reported sales adjusted for additional foreign currency impactCompany expects to repurchase up to $150 million of its common stock in Q2 2024 CHARLOTTE, N.C, May 02, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2024. First quarter net sales of $953 million decreased (2.
CHARLOTTE, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 2, 2024, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register.veve
FY23 net sales of $3,965 million increased 1.1%, organic sales increased 2.2%FY23 GAAP net income (loss) of ($132) million or ($0.62) per share, adjusted EPS of $1.83Q4 net sales of $1,012 million increased 2.9%, organic sales increased 1.9%Q4 GAAP net income of $67 million or $0.32 per share, adjusted EPS of $0.44FY24 outlook: organic sales flat to up 1.5%; adjusted EPS of $2.00 to $2.10 CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the fourth quarter and full year of 2023. Full year 2023 net sales of $3,965 million increased 1.1% (organic sales increased 2.2%), compar